BPMX:NYE-BioPharmX Corporation (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 0.51

Change

0.00 (0.00)%

Market Cap

USD 0.78M

Volume

3.91M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

BioPharmX Corporation (BPMX) Stock Analysis:
Based on the BioPharmX Corporation stock forecasts from 0 analysts, the average analyst target price for BioPharmX Corporation is not available over the next 12 months. BioPharmX Corporation’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BioPharmX Corporation is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, BioPharmX Corporation’s stock price was USD 0.51. BioPharmX Corporation’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for BioPharmX Corporation
No recent average analyst rating found for BioPharmX Corporation

About

BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase I ...Read More

Company Website : http://www.biopharmx.com

Address : 115 Nicholson Lane, San Jose, CA, United States, 95134

Employees : 3

Fiscal Year End : January

Currency: USD

Country : USA

Technical Indicators

Beta : 0.63

Short Ratio : 1.33

Shorted Shares : 91,024

200 Day Moving Average : 0.77

Shorted Shares Previous Month : 86,618

50 Day Moving Average : 3.64

Shares Held By Insiders : 12.74%

Short Percentage : 6.80%

Shares Held by Institutions : 1.93%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.90 (+0.93%)

 USD169.87B 34.44 4.06
DNA Ginkgo Bioworks Holdings

-0.26 (-4.91%)

 USD9.68B N/A N/A
BHVN Biohaven Pharmaceutical Holdin..

-2.96 (-2.51%)

 USD7.73B N/A N/A
RCUS Arcus Biosciences Inc

-0.86 (-2.50%)

 USD2.52B N/A N/A
MYOV Myovant Sciences Ltd

-0.33 (-2.24%)

 USD1.43B N/A N/A
ADCT ADC Therapeutics SA

-0.16 (-0.94%)

 USD1.32B -99,999.99 N/A
ZYME Zymeworks Inc

+0.07 (+0.52%)

 USD0.70B 300.20 N/A
PFNX Pfenex Inc

N/A

 USD0.44B 268.67 63.90
LCTX Lineage Cell Therapeutics Inc

-0.08 (-4.49%)

 USD0.32B 3.63 N/A
CVM CEL-SCI Corporation

+0.21 (+3.55%)

 USD0.29B N/A N/A

ETFs Containing BPMX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 14.61% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.61% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.62% N/A N/A N/A N/A
Risk Adjusted Return 54.87% N/A N/A N/A N/A
Market Capitalization 0.78M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.90 N/A N/A N/A N/A
Price / Cash Flow Ratio -0.08 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -2,020.23% N/A N/A N/A N/A
Return on Invested Capital -1,704.13% N/A N/A N/A N/A
Return on Assets -209.33% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.33 N/A N/A N/A N/A
Short Percent 6.80% N/A N/A N/A N/A
Beta 0.63 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.